Nestlé breaks into diagnostics, acquiring Prometheus for rumoured $1bn

Food giant Nestlé is expanding its presence in the healthcare market by agreeing to buy US gastrointestinal and cancer diagnostics specialist Prometheus Laboratories. Although the Swiss group has not disclosed financial terms of the deal, a figure of around $1bn for the merger consideration has been touted by analysts and the press.